Literature DB >> 22033024

Simplified quantification and whole-body distribution of [18F]FE-PE2I in nonhuman primates: prediction for human studies.

Andrea Varrone1, Balázs Gulyás, Akihiro Takano, Michael G Stabin, Cathrine Jonsson, Christer Halldin.   

Abstract

INTRODUCTION: [(18)F]FE-PE2I is a promising dopamine transporter (DAT) radioligand. In nonhuman primates, we examined the accuracy of simplified quantification methods and the estimates of radiation dose of [(18)F]FE-PE2I.
METHODS: In the quantification study, binding potential (BP(ND)) values previously reported in three rhesus monkeys using kinetic and graphical analyses of [(18)F]FE-PE2I were used for comparison. BP(ND) using the cerebellum as reference region was obtained with four reference tissue methods applied to the [(18)F]FE-PE2I data that were compared with the kinetic and graphical analyses. In the whole-body study, estimates of adsorbed radiation were obtained in two cynomolgus monkeys.
RESULTS: All reference tissue methods provided BP(ND) values within 5% of the values obtained with the kinetic and graphical analyses. The shortest imaging time for stable BP(ND) estimation was 54 min. The average effective dose of [(18)F]FE-PE2I was 0.021 mSv/MBq, similar to 2-deoxy-2-[(18)F]fluoro-d-glucose.
CONCLUSIONS: The results in nonhuman primates suggest that [(18)F]FE-PE2I is suitable for accurate and stable DAT quantification, and its radiation dose estimates would allow for a maximal administered radioactivity of 476 MBq in human subjects.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22033024     DOI: 10.1016/j.nucmedbio.2011.08.004

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

1.  Simplified estimation of binding parameters based on image-derived reference tissue models for dopamine transporter bindings in non-human primates using [18F]FE-PE2I and PET.

Authors:  Ikuo Odano; Andrea Varrone; Tetsuo Hosoya; Kazuya Sakaguchi; Balázs Gulyás; Parasuraman Padmanabhan; Krishna Kanta Ghosh; Chang-Tong Yang; Ilonka Guenther; Zhimin Wang; Raymond Serrano; Nevil Ghislain Chimon; Christer Halldin
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-12-20

2.  Development of a clinically feasible [11C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction.

Authors:  My Jonasson; Lieuwe Appel; Torsten Danfors; Dag Nyholm; Håkan Askmark; Andreas Frick; Jonas Engman; Tomas Furmark; Jens Sörensen; Mark Lubberink
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-12-20

3.  Simplified quantification of [18F]FE-PE2I PET in Parkinson's disease: Discriminative power, test-retest reliability and longitudinal validity during early peak and late pseudo-equilibrium.

Authors:  Joachim Brumberg; Vera Kerstens; Zsolt Cselényi; Per Svenningsson; Mathias Sundgren; Patrik Fazio; Andrea Varrone
Journal:  J Cereb Blood Flow Metab       Date:  2020-09-21       Impact factor: 6.200

4.  EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0.

Authors:  Silvia Morbelli; Giuseppe Esposito; Javier Arbizu; Henryk Barthel; Ronald Boellaard; Nico I Bohnen; David J Brooks; Jacques Darcourt; John C Dickson; David Douglas; Alexander Drzezga; Jacob Dubroff; Ozgul Ekmekcioglu; Valentina Garibotto; Peter Herscovitch; Phillip Kuo; Adriaan Lammertsma; Sabina Pappata; Iván Peñuelas; John Seibyl; Franck Semah; Livia Tossici-Bolt; Elsmarieke Van de Giessen; Koen Van Laere; Andrea Varrone; Michele Wanner; George Zubal; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-09       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.